Estimating drug sales of multiple sclerosis from 2012-2021.
By Daniel Chancellor, Lead Analyst
5 September 2014
I am a Lead Analyst covering the CNS and rare disease markets at Datamonitor Healthcare. I joined in early 2010, having ...
Read full bio
A strong growth trajectory, aided by the launch of novel oral therapies, is expected within the multiple sclerosis (MS) market until 2018, by which time the market will peak at $20.8bn. The forecast period will see injectable treatments such as Avonex and Copaxone increasingly being eschewed in favor of novel oral treatments such as Gilenya and Tecfidera, with Tecfidera accounting for 33% of market value by 2021.
Datamonitor Healthcare has used a company-reported sales-based approach to estimate drug sales for MS in the US, Japan, and five major EU markets from 2012 to 2021.
How will our multiple sclerosis forecast report benefit you?
- Stay ahead of competition
Identify the sales patterns forecast up to 2021 and the rationale behind our predictions, allowing you to stay ahead of the competition by preparing for dips and peaks in the market.
- Discover new products
Understand how the emergence of oral therapies will affect MS market growth as well as brands already on the market, enabling you to identify new types of products with the most commercial potential.
- Benchmark your product
Explore the factors contributing to Tecfidera becoming the dominant MS therapy above other oral therapies and injectable drugs, allowing you to benchmark your product against that with the most commercial success.
Key questions answered
- How will recently launched injectable Plegridy perform during the forecast period?
- What effect will generic and biosimilar launches have on specific products?
- How will the launches of novel oral therapies affect the market share of injectable treatments such as Avonex and Copaxone?
|Drug List:||Companies Mentioned:|